Wenying Chai

Ms. Wenying Chai


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
YMYun Ma
Yun Ma
WCWenying Chai
Wenying Chai
DBDeyong Bu
Deyong Bu
XFXuemin Feng
Xuemin Feng
JAJ. Wesson Ashford
J. Wesson Ashford
XZXianbo Zhou
Xianbo Zhou
Objective: To study the effects of chemotherapy on cognitive function in breast cancer patients, and to investigate the relationship of MemTrax test of memory and related functions to the FACT-Cog functional self-assessment for the evaluation and management of chemobrain. Methods: In this prospective cohort study, clinical information of pathologically confirmed female breast cancer patients who decided to receive chemotherapy were collected in a questionnaire which was developed for this study and provided as a supplementary file. The FACT-Cog self-assessment and MemTrax test were administered before and after the chemotherapy treatments. Patients with chemobrain were identified using published criteria based on FACT-Cog scores, and MemTrax scores from chemobrain patients were analyzed. Results: Fifty-six patients participated in this study, of which 41 participants completed 4 or more cycles of chemotherapy and were included in the final analyses here. Using the reported high end of minimal clinical differences (10.6 points) of FACT-Cog before and after chemotherapy, 18 patients suffered from chemobrain in this study. In these 18 chemobrain patients, no cognitive impairments were detected by MemTrax, which paradoxically demonstrated an improvement in the normal cognitive range. Conclusion: The cognitive impairment induced by chemotherapy in breast cancer patients is detectable by the FACT-Cog in a Chinese cohort but is not detected by the MemTrax memory test. The fact that the more objective MemTrax could not detect the impairment could alleviate patients’ concerns which in turn would be beneficial for patients’ mental health.

23 May 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
XMXiaojia Ma
Xiaojia Ma
LWLuyao Wang
Luyao Wang
YHYanbo Hao
Yanbo Hao
WCWenying Chai
Wenying Chai
MHMin Huang
Min Huang
Breast cancer (BC) is a malignancy associated with high morbidity and mortality. Rubia yunnanensis (RY), a traditional Chinese medicinal herb, has demonstrated inhibitory effects against various tumor types, yet its role in BC remains undefined. This study investigated the effect of RY on BC and elucidated its underlying molecular regulatory mechanisms. The role of RY in BC was assessed through CCK-8, Transwell, flow cytometry, Western blot, xenograft modeling, and immunohistochemistry assays. We employed ultra-high-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF/MS), the PubChem and TCMSP database, and literature mining to identify the active ingredients of RY. Potential targets for these active ingredients were predicted using TargetPrediction database, while BC-regulated targets were collected from the GeneCards, DrugBank, and TTD databases. A protein-protein interaction network analysis identified core targets, followed by GO and KEGG enrichment analyses using the DAVID database. Molecular docking was performed to validate the binding affinity of the active ingredients for these core targets. Finally, Western blot analysis was used to detect the relative protein expression levels of the core targets. RY significantly reduced the viability of MDA-MB-231 and BT-549 cells, inhibited their migratory capacity, promoted apoptosis, and upregulated the expression of the E-cadherin, while downregulating the expression of N-cadherin and vimentin. These effects were concentration-dependent. In vivo studies demonstrated that RY treatment inhibited BC growth, reduced the Ki67-positive rate and the expression of N-cadherin and vimentin in mouse BC tissues, and promoted the expression of E-cadherin. Furthermore, UPLC-Q-TOF/MS analysis and database mining identified 26 active components in RY and 312 potential targets related to its action against BC. The core targets for RY in BC treatment include TP53, AKT1, IL-6, TNF, STAT3, CTNNB1, EGFR, MYC, ESR1, and CASP3. Enrichment analysis indicated significant involvement of the PI3K-AKT and MAPK signaling pathways. The key active components of RY demonstrated strong binding potential with these core target genes, namely TNF, ESR1, CASP3, EGFR, STAT3, MYC, CTNNB1, AKT1, TP53, and IL-6. This study reveals that RY exhibits therapeutic potential on BC through multi-ingredient, multi-target, and multi-pathway mode of action.